中国组织工程研究 ›› 2025, Vol. 29 ›› Issue (26): 5704-5712.doi: 10.12307/2025.699

• 组织构建综述 tissue construction review • 上一篇    下一篇

O连接N-乙酰葡萄糖胺糖基化在神经退行性疾病中的作用及临床应用前景

蒋千平1,杨  丹2,3,4,万石磊1,徐丹丹2,3,4,5,曹  璐3,6,周  晶2,3,4,5   

  1. 湖北中医药大学,1针灸骨伤学院,5第一临床学院,6基础医学院,湖北省武汉市  430065;2湖北省中医院推拿科/康复医学科,湖北省武汉市  430061;3湖北时珍实验室,湖北省武汉市  430065;4湖北中医药大学附属医院,湖北省武汉市  430061
  • 收稿日期:2024-07-27 接受日期:2024-09-14 出版日期:2025-09-18 发布日期:2025-02-28
  • 通讯作者: 周晶,博士,博士生导师,教授,主任医师,湖北省中医院推拿科/康复医学科,湖北省武汉市 430061;湖北时珍实验室,湖北省武汉市 430065;湖北中医药大学附属医院,湖北省武汉市 430061;湖北中医药大学第一临床学院,湖北省武汉市 430065 并列通讯作者:曹璐,博士,助理研究员,湖北时珍实验室,湖北省武汉市 430065;湖北中医药大学基础医学院,湖北省武汉市 430065
  • 作者简介:蒋千平,男,2000年生,江苏省溧阳市人,汉族,湖北中医药大学在读硕士,主要从事肌萎缩侧索硬化中西医结合治疗方面的研究。
  • 基金资助:
    2023年湖北省自然科学基金计划(联合基金项目)(2023AFD128),项目负责人:周晶;2023年湖北省自然科学基金计划(联合基金项目)(2023AFD143),项目负责人:曹璐;2024年湖北省自然科学基金计划(联合基金项目)(2024AFD279),项目负责人:徐丹丹

Role of O-linked N-acetylglucosamine glycosylation in neurodegenerative diseases and its clinical application prospects

Jiang Qianping1, Yang Dan2, 3, 4, Wan Shilei1, Xu Dandan2, 3, 4, 5, Cao Lu3, 6, Zhou Jing2, 3, 4, 5   

  1. 1School of Acupuncture-Moxibustion and Orthopedics, Hubei University of Chinese Medicine, Wuhan 430065, Hubei Province, China; 2Department of Tuina and Rehabilitation Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, Hubei Province, China; 3Hubei Sizhen Laboratory, Wuhan 430065, Hubei Province, China; 4Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan 430061, Hubei Province, China; 5First Clinical Medical College, Hubei University of Chinese Medicine, Wuhan 430065, Hubei Province, China; 6School of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan 430065, Hubei Province, China
  • Received:2024-07-27 Accepted:2024-09-14 Online:2025-09-18 Published:2025-02-28
  • Contact: Zhou Jing, MD, Doctoral supervisor, Professor, Chief physician, Department of Tuina and Rehabilitation Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, Hubei Province, China; Hubei Sizhen Laboratory, Wuhan 430065, Hubei Province, China; Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan 430061, Hubei Province, China Co-corresponding author: Cao Lu, MD, Assistant researcher, Hubei Sizhen Laboratory, Wuhan 430065, Hubei Province, China; School of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan 430065, Hubei Province, China
  • About author:Jiang Qianping, Master’s candidate, School of Acupuncture-Moxibustion and Orthopedics, Hubei University of Chinese Medicine, Wuhan 430065, Hubei Province, China
  • Supported by:
    2023 Natural Science Foundation of Hubei Province (Joint Fund Project), Nos. 2023AFD128 (to ZJ) and 2023AFD143 (to CL); 2024 Natural Science Foundation of Hubei Province (Joint Fund Project), No. 2023AFD279 (to XDD)

摘要:


文题释义:
O连接N-乙酰葡萄糖胺糖基化:是一种蛋白质翻译后修饰,指N-乙酰葡萄糖胺通过O-糖苷键与蛋白质分子中的丝氨酸(Ser)或苏氨酸(Thr)残基上的羟基相连的过程,其在蛋白质的加工、定位、稳定性、活性以及细胞信号传导等方面扮演着重要角色。 
神经退行性疾病:是一组涉及中枢或周围神经系统结构的慢性、进行性疾病,主要特征为神经细胞的逐步退化、丢失以及神经通路的功能障碍,通常不可逆转,并且随着时间的推移逐渐加剧,最终导致受影响个体出现明显的神经功能障碍。

背景:蛋白质的异常聚集与神经元丢失是神经退行性疾病的典型病理改变,而O连接N-乙酰葡萄糖胺糖基化水平的变化与相关病理改变关系密切,有望成为潜在的治疗靶点。
目的:围绕O连接N-乙酰葡萄糖胺糖基化在神经退行性疾病中的作用以及目前临床运用进展进行综述,旨在为神经退行性疾病的治疗提供新的思路。
方法:由第一作者检索中国知网、维普数据库、万方数据库、中国临床试验注册中心(ChiCTR)、Web of Science、PubMed、Cochrane Library与Clinical Trials、国际神经退行性疾病Alzforum网站,以“O连接N-乙酰葡萄糖胺糖基化,O-GlcNAc糖基化,神经退行性疾病,阿尔茨海默病,帕金森病,肌萎缩侧索硬化症,亨廷顿病,O连接N-乙酰葡萄糖胺糖苷水解酶抑制剂,临床试验”为中文检索词,以“O-GlcNAcylation,Neurodegenerative diseases,Alzheimer disease,Parkinson disease,Amyotrophic lateral sclerosis,Huntington disease,OGA inhibitors,Clinical trial”为英文检索词,最终纳入66篇文献进行综述。
结果与结论:①O连接N-乙酰葡萄糖胺糖基化参与了神经元的发育与功能调节,并随着神经元发育成熟,其水平逐渐降低;②神经退行性疾病中相关病理蛋白受到O连接N-乙酰葡萄糖胺糖基化的调控,多数证据表明使用O连接N-乙酰葡萄糖胺糖苷水解酶抑制剂提高O连接N-乙酰葡萄糖胺糖基化水平可以显著减轻相关病理改变,能够成为神经退行性疾病潜在的治疗策略;③部分O连接N-乙酰葡萄糖胺糖苷水解酶抑制剂已完成Ⅰ期临床试验,表现出了良好的安全性与耐受性。

https://orcid.org/0009-0007-7482-7384(蒋千平)

中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程

关键词: O连接N-乙酰葡萄糖胺糖基化, 神经退行性疾病, 阿尔茨海默病, 帕金森病, 肌萎缩侧索硬化症, 亨廷顿病, 综述

Abstract: BACKGROUND: The abnormal aggregation of proteins and the loss of neurons are typical pathological changes observed in neurodegenerative diseases. Changes in the levels of O-linked N-acetylglucosamine glycosylation are closely related to relevant pathological changes and are promising potential therapeutic targets.
OBJECTIVE: To review the role of O-linked N-acetylglucosamine glycosylation in neurodegenerative diseases and the current advancements in its clinical applications, aiming to provide new insights for the treatment of neurodegenerative disorders.
METHODS: The first author conducted a literature search in the CNKI, VIP, WanFang Database, ChiCTR, Web of Science, PubMed, Cochrane Library, Clinical Trials and Alzforum, using the search terms “O-GlcNAcylation, Neurodegenerative diseases, Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis, Huntington’s disease, OGA inhibitors, Clinical trial” in Chinese and English. A total of 66 relevant articles were included for review.
RESULTS AND CONCLUSION: O-linked N-acetylglucosamine glycosylation is involved in the development and functional regulation of neurons, and its levels gradually decrease as neuronal development matures. In neurodegenerative diseases, the pathological proteins involved are regulated by O-linked N-acetylglucosamine glycosylation. Most evidence suggests that using O-GlcNAcase inhibitors to enhance O-linked N-acetylglucosamine glycosylation levels can significantly alleviate related pathological changes, making it a potential therapeutic strategy for neurodegenerative diseases. Some O-GlcNAcase inhibitors have completed Phase I clinical trials, demonstrating good safety and tolerability.

Key words: O-linked N-acetylglucosamine glycosylation, neurodegenerative diseases, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, review

中图分类号: